Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP3021 in Geographic Atrophy Secondary to AMD in Japan
NCT06970665Phase 4Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 4 trial of avacincaptad pegol in geographic atrophy (GA), sponsored by Astellas Pharma. Started Jul 2025; status: active, not recruiting.
02
Drugs
avacincaptad pegol
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT06970665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06970665.